HeartBeam Inc. Strengthens Cardiac Diagnostics with Two New U.S. Patents

HeartBeam Inc. (NASDAQ: BEAT), a leader in cardiac technology innovation, has recently been granted two new U.S. patents, significantly bolstering its intellectual property portfolio and reinforcing its stance in the cardiac diagnostics sector. These patents cover the company's groundbreaking credit card-sized, cable-free 3D ECG device and its advanced rhythm analysis algorithm, designed to provide high-fidelity electrical signal capture from three noncoplanar directions and continuous signal input analysis, respectively.

The first patent underscores HeartBeam's commitment to revolutionizing cardiac monitoring with its portable, high-precision 3D ECG device. This device, capable of capturing detailed electrical signals from chest and finger electrodes, represents a leap forward in making heart health monitoring more accessible and accurate outside traditional clinical settings. The second patent highlights the company's innovative approach to rhythm analysis, offering a continuous, algorithm-based analysis that could significantly enhance the detection and understanding of cardiac arrhythmias.

With these patents, HeartBeam now holds over 20 U.S. and international patents, with more applications in the pipeline, signaling its ongoing dedication to advancing cardiac care technology. The company's focus on delivering personalized insights into heart health through its 3D ECG platform is set to transform the landscape of cardiac diagnostics, offering patients and healthcare providers powerful tools for early detection and management of heart conditions.

For further details on HeartBeam's advancements and its impact on the cardiac technology field, visit https://ibn.fm/6xni4. HeartBeam's continuous innovation in cardiac diagnostics underscores the importance of technological advancements in improving patient outcomes and streamlining healthcare delivery.